Advertisement

Benefits of statins in chronic obstructive pulmonary disease patients with pulmonary hypertension: A meta-analysis

Published:October 31, 2019DOI:https://doi.org/10.1016/j.ejim.2019.09.009

      Highlights

      • Statins significantly decreased SPAP in COPD-PH.
      • Statins significantly improved 6MWD in COPD-PH.
      • Statins was beneficial in the management of COPD-associated PH.

      Abstract

      Purpose

      This meta-analysis was performed to evaluate the efficacy of statins in chronic obstructive pulmonary disease (COPD) patients with pulmonary hypertension (PH).

      Methods

      A systematic search was made of MEDLINE, Cochrane, ISI Web of Science and SCOPUS databases. Randomized clinical trials on treatment of COPD-PH with the statins, compared with placebo, were reviewed. Studies were pooled to weighted mean differences (WMD), with 95% confidence interval (CI).

      Results

      Five trials (enrolling 270 participants) met the inclusion criteria.
      Compared with placebo, the statins presented significant effects on systolic pulmonary artery pressure (WMD -4.52 mmHg; 95% CI -6.32 to -2.72 mmHg) and 6-min walk distance (6MWD) (WMD 32.46 m; 95% CI 13.63–51.29 m).

      Conclusions

      Statins therapy significantly improves PH and 6MWD in COPD patients with PH.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vogelmeier C.F.
        • Criner G.J.
        • Martinez F.J.
        • et al.
        Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. gold executive summary.
        Am J Respir Crit Care Med. 2017; 195: 557-582
        • Simonneau G.
        • Gatzoulis M.A.
        • Adatia I.
        • et al.
        Updated clinical classification of pulmonary hypertension.
        J Am Coll Cardiol. 2013; 62: D34-D41
        • Nathan S.D.
        • Barbera J.A.
        • Gaine S.P.
        • et al.
        Pulmonary hypertension in chronic lung disease and hypoxia.
        Eur Respir J. 2019; 53
        • Chaouat A.
        • Bugnet A.S.
        • Kadaoui N.
        • et al.
        Severe pulmonary hypertension and chronic obstructive pulmonary disease.
        Am J Respi Crit Care Med. 2005; 172: 189-194
        • Oswald-Mammosser M.
        • Weitzenblum E.
        • Quoix E.
        • et al.
        Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure.
        Chest. 1995; 107: 1193-1198
        • Girgis R.
        Statin therapy in pulmonary hypertension.
        PVRI Rev. 2009; 1: 199-202
        • Murata T.
        • Kinoshita K.
        • Hori M.
        • et al.
        Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension..
        Arterioscler Thromb Vasc Biol. 2005; 25: 2335-2342
        • Katsiki N.
        • Wierzbicki A.S.
        • Mikhailidis D.P.
        Pulmonary arterial hypertension and statins: an update.
        Curr Opin Cardiol. 2011; 26: 322-326
        • Li X.L.
        • Guan R.J.
        • Li J.J.
        Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
        J Cardiovasc Pharmacol. 2012; 60: 219-226
        • Chen D.
        • Zhou D.
        • Qian J.
        • et al.
        Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles.
        Exp Lung Res. 2012; 38: 333-343
        • Yao J.
        • Xiong M.
        • Tang B.
        • et al.
        Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and -9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats.
        Eur J Cardio-Thorac Surg. 2012; 42: e121-e127
        • Arian A.
        • Moghadam S.G.
        • Kazemi T.
        • Hajihosseini M.
        The effects of statins on pulmonary artery pressure in patients with chronic obstructive pulmonary disease: a randomized controlled trial.
        J Res Pharm Pract. 2017; 6: 27-30
        • Lee T.M.
        • Chen C.C.
        • Shen H.N.
        • Chang N.C.
        Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
        Clin Sci (Lond, Engl: 1979). 2009; 116: 497-505
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: the prisma statement.
        Ann Intern Med. 2009; 151 (W264): 264-269
        • Detsky A.S.
        • Naylor C.D.
        • O'Rourke K.
        • McGeer A.J.
        • L'Abbe K.A.
        Incorporating variations in the quality of individual randomized trials into meta-analysis.
        J Clin Epidemiol. 1992; 45: 255-265
        • Chogtu B.
        • Kuriachan S.
        • Magazine R.
        • et al.
        A prospective, randomized study: evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
        Indian J Pharmacol. 2016; 48: 503-508
        • Liu H.F.
        • Qi X.W.
        • Ma L.L.
        • Yao D.K.
        • Wang L.
        Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease.
        Exp Clin Cardiol. 2013; 18: e40-e43
        • Moosavi S.A.
        • Raji H.
        • Faghankhani M.
        • Yazdani R.
        • Esmaeili M.
        Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: a randomized controlled trial.
        Iran Red Crescent Med J. 2013; 15: 649-654
        • Cassady S.J.
        • Reed R.M.
        Pulmonary hypertension in COPD: a case study and review of the literature.
        Medicina (Kaunas). 2019; 55
        • Greiner S.
        • Jud A.
        • Aurich M.
        • et al.
        Reliability of noninvasive assessment of systolic pulmonary artery pressure by doppler echocardiography compared to right heart catheterization: analysis in a large patient population.
        J Am Heart Assoc. 2014; 3
        • Liao J.K.
        • Laufs U.
        Pleiotropic effects of statins.
        Annu Rev Pharmacol Toxicol. 2005; 45: 89-118
        • Nishimura T.
        • Vaszar L.T.
        • Faul J.L.
        • et al.
        Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.
        Circulation. 2003; 108: 1640-1645
        • Chaouat A.
        • Naeije R.
        • Weitzenblum E.
        Pulmonary hypertension in copd.
        Eur Respir J. 2008; 32: 1371-1385
        • Barbera J.A.
        • Blanco I.
        Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.
        Drugs. 2009; 69: 1153-1171
        • Shujaat A.
        • Bajwa A.A.
        • Cury J.D.
        Pulmonary hypertension secondary to copd.
        Pulm Med. 2012; 2012203952
        • Palange P.
        • Testa U.
        • Huertas A.
        • et al.
        Circulating haemopoietic and endothelial progenitor cells are decreased in copd.
        Eur Respir J. 2006; 27: 529-541
        • Janssen W.J.
        • Yunt Z.X.
        • Muldrow A.
        • et al.
        Circulating hematopoietic progenitor cells are decreased in COPD.
        Copd. 2014; 11: 277-289
        • Wang X.X.
        • Zhang F.R.
        • Shang Y.P.
        • et al.
        Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial.
        J Am Coll Cardiol. 2007; 49: 1566-1571
        • Assmus B.
        • Urbich C.
        • Aicher A.
        • et al.
        HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.
        Circ Res. 2003; 92: 1049-1055
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • et al.
        The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        Ann Intern Med. 2009; 151: W65-W94